| Overview |
| bsm-63036r |
| VEGFA Recombinant Antibody |
| IHC-P, IHC-F, IF |
| Human |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human VEGF |
| Recombinant |
| IgG |
| Lot dependent |
| Purified by Protein A. |
| 0.01M TBS (pH 7.4), 1% BSA, 0.02% Proclin 300, and 50% Glycerol |
| Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| Secreted |
| Vascuoar endothelial growth factor A; VEGF A; vascular endothelial growth factor A isoform 2 precursor; MGC70609; MVCD1; VEGF; VPF; VEGFA_HUMAN; VEGF-A; Vascular permeability factor (VPF); |
| Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. |
| Application Dilution |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF |
|